New targeted therapies in pituitary carcinoma resistant to temozolomide

Pituitary

Volumn 15, Issue 1, 2012, Pages 37-43

  Jouanneau, Emmanuel ^a,b,c   Wierinckx, Anne ^a,c,d   Ducray, François ^a,b,c   Favrel, Véronique ^e   Borson Chazot, Françoise ^b,c   Honnorat, Jérôme ^a,b,c   Trouillas, Jacqueline ^a,b,c   Raverot, Gérald ^a,b,c  

^a LYON NEUROSCIENCE RESEARCH CENTER   (France)

^b HOSPICES CIVILS DE LYON   (France)

^c UNIVERSITÉ DE LYON   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

Everolimus; mTOR; Pituitary adenoma; Pituitary carcinoma; Silent ACTH tumor; Temozolomide

Indexed keywords

CORTICOTROPIN; EVEROLIMUS; HYDROCORTISONE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TEMOZOLOMIDE;

ACTH PITUITARY CARCINOMA; ACTH SECRETING ADENOMA; ADRENALECTOMY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DIARRHEA; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME ACTIVATION; GENE EXPRESSION; HEADACHE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCORTISOLISM; HYPOPHYSIS TUMOR; INTRACELLULAR SIGNALING; MALE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR RECURRENCE; VISUAL FIELD DEFECT;

DACARBAZINE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; SIROLIMUS;

EID: 84858160987     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0341-0     Document Type: Article

References (20)

1. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90(5):3089-3099. doi: 10.1210/jc.2004-2231
2. Kaltsas GA, Mukherjee JJ, Plowman PN, Monson JP, Grossman AB, Besser GM (1998) The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. J Clin Endocrinol Metab 83(12):4233-4238 (Pubitemid 29100114)
3. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7(6):518-520 (Pubitemid 43796152)
4. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia J-G, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592-4599
5. Bush ZM, Longtine JA, Cunningham T, Schiff D, Jane JA, Vance ML, Thorner MO, Laws ER, Lopes MBS (2010) Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O6-methylguanine methyltransferase (MGMT) promoter methylation and expression. J Clin Endocrinol Metab 95(11):E280-E290. doi:10.1210/jc.2010-0441
6. Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M (2010) Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol 163(6):843-851. doi:10.1530/eje-10-0629
7. Dworakowska D, Wlodek E, Leontiou CA, Igreja S, Cakir M, Teng M, Prodromou N, Goth MI, Grozinsky-Glasberg S, Gueorguiev M, Kola B, Korbonits M, Grossman AB (2009) Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors. Endocr Relat Cancer 16(4):1329-1338. doi:ERC-09-0101[pii]10. 1677/ERC-09-0101
8. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514-523. doi:10.1056/NEJMoa 1009290
9. Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I (2009) Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro. Endocr Relat Cancer 16(3):1017-1027. doi:ERC-08-0269[pii]10.1677/ERC-08-0269
10. Zatelli MC, Minoia M, Filieri C, Tagliati F, Buratto M, Ambrosio MR, Lapparelli M, Scanarini M, degli Uberti EC (2010) Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 95(2):968-976. doi:10.1210/ jc.2009-1641
11. Cerovac V, Monteserin-Garcia J, Rubinfeld H, Buchfelder M, Losa M, Florio T, Paez-Pereda M, Stalla GK, Theodoropoulou M (2010) The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells. Cancer Res 70(2):666-674. doi:0008-5472.CAN-09-2951[pii]10.1158/0008-5472.CAN- 09-2951
12. Jouanneau E, Ducluzeau PH, Tilikete C, Borson-Chazot F, Trouillas J, Perrin G (2001) Should silent corticotroph-cell adenoma be classified as a non-functional pituitary adenoma? Neurochirurgie 47(2-3 Pt 1):128-132
13. Raverot G, Wierinckx A, Jouanneau E, Auger C, Borson-Chazot F, Lachuer J, Pugeat M, Trouillas J (2010) Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease. Eur J Endocrinol doi:10.1530/EJE-10-0076
14. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, Hussain S, Sheppard MC, Franklyn JA, Gittoes NJ (2002) Vascular endothelial growth factor, its receptor KDR/Flk- 1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87(9):4238-4244
15. Zatelli MC, Piccin D, Vignali C, Tagliati F, Ambrosio MR, Bondanelli M, Cimino V, Bianchi A, Schmid HA, Scanarini M, Pontecorvi A, De Marinis L, Maira G, degli Uberti EC (2007) Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion. Endocr Relat Cancer 14(1):91-102. doi:14/1/91[pii]10.1677/ERC-06- 0026
16. Luque GM, Perez-Millan MI, Ornstein AM, Cristina C, Becu- Villalobos D (2011) Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. J Pharmacol Exp Ther 337(3):766-774. doi:10.1124/ jpet.110.177790
17. Fukuoka H, Cooper O, Mizutani J, Tong Y, Ren SG, Bannykh S, Melmed S (2011) HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol doi:me.2010-0353 [pii]10.1210/me. 2010-0353
18. Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, Melmed S (2011) Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci USA 108(20):8414-8419. doi:10180911 08[pii]10.1073/pnas.1018091108
19. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95(4):1708-1716. doi:jc.2009-1191 [pii]10.1210/jc.2009- 1191
20. Wierinckx A, Raverot G, Nazaret N, Jouanneau E, Auger C, Lachuer J, Trouillas J (2010) Proliferation markers of human pituitary tumors: contribution of a genome-wide transcriptome approach. Mol Cell Endocrinol doi:10.1016/j.mce.2010.02.043